Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: Results from TIME-CHF

European Journal of Heart Failure

Volumn 15, Issue 8, 2013, Pages 910-918

  Sanders Van Wijk, Sandra ^a   Muzzarelli, Stefano ^b,c   Neuhaus, Michael ^d   Kiencke, Stephanie ^e   Maeder, Micha ^f   Estlinbaum, Werner ^g   Tobler, Daniel ^b   Mayer, Kurt ^h   Erne, Paul ⁱ   Pfisterer, Matthias E ^b   Brunner La Rocca, Hans Peter ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c DIVISION OF CARDIOLOGY   (Switzerland)

^d Kantonsspital Baden   (Switzerland)

^e Kantonsspital Bruderholz ^*  (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g Kantonsspital Liestal   (Switzerland)

^h KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

ⁱ LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

Ageing; Co morbidities; Drug therapy; Heart failure; Natriuretic peptide; Safety

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIAC PATIENT; CLINICAL EFFECTIVENESS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIURETIC THERAPY; FEMALE; FOLLOW UP; GERIATRIC PATIENT; GROUPS BY AGE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

AGEING; CO-MORBIDITIES; DRUG THERAPY; HEART FAILURE; NATRIURETIC PEPTIDE; SAFETY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84881015911     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft079     Document Type: Article

References (36)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the D, Treatment of A, Chronic Heart Failure of the European Society of C, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14: 803-869.
2. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy C, Young JB. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007;297: 61-70.
3. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24: 464-474.
4. Pulignano G, Del Sindaco D, Tavazzi L, Lucci D, Gorini M, Leggio F, Porcu M, Scherillo M, Opasich C, Di Lenarda A, Senni M, Maggioni AP. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). AmHeart J 2002;143: 45-55.
5. Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J 2009;157:754-762 e2.
6. Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, Thebaut JF, Genoun M. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey. Arch Cardiovasc Dis 2012;105: 355-365.
7. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635-641.
8. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008;52: 997-1003.
9. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, KatusHA. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004;110: 1780-1786.
10. Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009;119: 2471-2479.
11. White M, Rouleau JL, Afzal R, Floras J, Yusuf S, McKelvie RS. Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. Ther Adv Cardiovasc Dis 2009;3: 113-121.
12. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355: 1126-1130.
13. Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, Lok DJ, Crijns HJ, van Kraaij DJ, de Jonge N, Meeder JG, Prins M, Pinto YM. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 2010;56: 2090-2100.
14. Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011;58: 1881-1889.
15. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, JuilliereY. Plasma brain natriuretic peptide-guided therapy to improve outcomein heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49: 1733-1739.
16. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009;55: 53-60.
17. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158: 422-430.
18. Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010;170: 507-514.
19. Maeder MT, Mueller C, Pfisterer ME, Buser PT, Brunner-La Rocca HP. Use of B-type natriuretic peptide outside of the emergency department. Int J Cardiol 2008;127: 5-16.
20. Cheng JW, Nayar M. Areviewof heart failure management in the elderly population. Am J Geriatr Pharmacother 2009;7: 233-249.
21. Leibundgut G, Pfisterer M, Brunner-La Rocca HP. Drug treatment of chronic heart failure in the elderly. Drugs Aging 2007;24: 991-1006.
22. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M. Management of elderly patients with congestive heart failure - design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 2006;151: 949-955.
23. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009;301: 383-92.
24. ICH Good Clinical Practice 2002; CPMP/ICH/135/95.
25. http://vassarstats.net/.
26. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158: 422-430.
27. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010;170: 507.
28. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010;55: 645-653.
29. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49: 1733-1739.
30. Karlström P, Alehagen U, Boman K, Dahlström U. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 2011;13: 1096-1103.
31. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, DahlströmU. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study-Guidelines andNT-proBNPAnaLysis inHeart Failure). Eur J Heart Fail 2010;12: 1300-1308.
32. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351: 543-551.
33. Muzzarelli S, Maeder MT, Toggweiler S, Rickli H, Nietlispach F, Julius B, Burkard T, Pfisterer ME, Brunner-La Rocca HP, TIME-CHF Investigators. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy. Am J Cardiol 2012;109: 693-698.
34. Maeder MT, Rickli H, Pfisterer ME, Muzzarelli S, Ammann P, Fehr T, Hack D, Weilenmann D, Dieterle T, Kiencke S, Estlinbaum W, Brunner-La Rocca HP, TIME-CHF Investigators. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Am Heart J 2012;163: 407-414.
35. Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Ryden L, Scherhag A, Soler-Soler J, Remme WJ. Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail 2004;6: 467-475.
36. Miani D, Fresco C, Lucci D, Albanese MC, Gonzini L, Fioretti PM, Maggioni AP, Tavazzi L. Clinical characteristics, management, and prognosis of octogenarians with acute heart failure admitted to cardiology wards: results from the Italian Survey on Acute Heart Failure. Am Heart J 2009;158: 126-132.